Memphasys Past Earnings Performance
Past criteria checks 0/6
Memphasys's earnings have been declining at an average annual rate of -31.1%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 61.2% per year.
Key information
-31.1%
Earnings growth rate
-12.2%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 61.2% |
Return on equity | -68.3% |
Net Margin | -613.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Memphasys makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -5 | 2 | 2 |
30 Sep 23 | 1 | -4 | 1 | 2 |
30 Jun 23 | 1 | -3 | 1 | 1 |
31 Mar 23 | 1 | -3 | 1 | 1 |
31 Dec 22 | 1 | -2 | 1 | 1 |
30 Sep 22 | 1 | -2 | 1 | 1 |
30 Jun 22 | 1 | -2 | 1 | 1 |
31 Mar 22 | 1 | -2 | 1 | 1 |
31 Dec 21 | 1 | -2 | 1 | 1 |
30 Sep 21 | 0 | -2 | 1 | 1 |
30 Jun 21 | 0 | -1 | 1 | 0 |
31 Mar 21 | 0 | -1 | 1 | 0 |
31 Dec 20 | 0 | -1 | 1 | 0 |
30 Sep 20 | 0 | -1 | 1 | 0 |
30 Jun 20 | 0 | -1 | 1 | 0 |
31 Mar 20 | 0 | -1 | 1 | 0 |
31 Dec 19 | 0 | -1 | 1 | 0 |
30 Sep 19 | 0 | -1 | 1 | 0 |
30 Jun 19 | 0 | -1 | 1 | 0 |
31 Mar 19 | 0 | -1 | 1 | 0 |
31 Dec 18 | 0 | -1 | 1 | 0 |
30 Sep 18 | 0 | -1 | 1 | 0 |
30 Jun 18 | 0 | 0 | 1 | 0 |
31 Mar 18 | 0 | -1 | 1 | 0 |
31 Dec 17 | 0 | -1 | 2 | 0 |
30 Sep 17 | 0 | -1 | 2 | 0 |
30 Jun 17 | 0 | -2 | 2 | 0 |
31 Mar 17 | 0 | -2 | 1 | 0 |
31 Dec 16 | 0 | -2 | 2 | 0 |
30 Sep 16 | 0 | -2 | 2 | 0 |
30 Jun 16 | 0 | -2 | 2 | 0 |
31 Dec 15 | 0 | -2 | 1 | 0 |
30 Sep 15 | 0 | -2 | 1 | 0 |
30 Jun 15 | 0 | -2 | 2 | 0 |
31 Dec 14 | 0 | -1 | 1 | 0 |
30 Sep 14 | 0 | -1 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Dec 13 | 1 | -3 | 2 | 1 |
30 Sep 13 | 1 | -3 | 2 | 1 |
30 Jun 13 | 1 | -2 | 2 | 1 |
Quality Earnings: IG7 is currently unprofitable.
Growing Profit Margin: IG7 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IG7 is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.
Accelerating Growth: Unable to compare IG7's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IG7 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: IG7 has a negative Return on Equity (-68.34%), as it is currently unprofitable.